PubMed Health⌕ Search

Biomedical subjects

V V Tuyen

Publications and source records attributed to V V Tuyen.

5 recordsLinked to original sources

Retinal S-antigen in human subretinal fluid.

Studies in experimental models of retinal detachment have proposed that the degree of visual recovery following retinal reattachment depends upon the extent of photoreceptor degeneration. A means of assessing this degeneration would help in establishing postoperative prognosis. S-antigen (S-Ag) is a unique retinal protein found in outer segment disc membranes and photoreceptor cells. In 36 cases of human rhegmatogenous retinal detachment, subretinal fluid (SRF) concentrations of S-Ag, measured by radioimmunoassay, ranged from 43 to 170 ng/ml (serum: 1-28 ng/ml). Analysis of variance showed a positive correlation with the duration of detachment (P less than 0.001). There was a two-fold increase in S-Ag concentrations during the first 2 weeks of detachment (P less than 0.005), with constant levels thereafter. These findings reflect progressive photoreceptor degeneration and/or ongoing synthesis of outer segment proteins in the detached retina that stop after the second week of detachment. SRF S-Ag levels may provide a prognostic indicator of visual recovery after reattachment as well as a sensitive measure of retinal metabolic activity during detachment.

Adult↗

Retinal S antigen identified as the 48K protein regulating light-dependent phosphodiesterase in rods.

Retinal S antigen chromatographically purified from whole retina, induces experimental autoimmune uveoretinitis in laboratory animals. The 48K protein, a soluble protein found in rod outer segments, is purified through its specific binding to photoexcited rhodopsin and is involved in the quenching of light-induced guanosine 3',5'-monophosphate-phosphodiesterase activity. Biochemical, immunological, functional, and pathological tests showed that retinal S antigen and the 48K protein are identical.

3',5'-Cyclic-GMP Phosphodiesterases↗

[Activity of different antigenic preparations from the retina to induce experimental auto-immune uveo-retinitis (EAU) in guinea pigs (author's transl)].

24 different antigenic preparations from bovine or guinea pig retina and 3 from bovine uvea were tested for their ability to induce uveo-retinitis in guinea pigs. Each animal received one injection into the hind foot pads of 0.1 ml og the tissue preparation mixed with an equal volume of complete Freund's adjuvant. The intensity of the disease was assessed by clinical and histological criteria. Homogenates and extracts from whole guinea pig retina are more active than the same preparations from bovine retina. Autologous retinal extract is slightly more active than homologous in low doses. In bovine retina, the autoantigen(s) is localized in the photoreceptor structures and the pigment epithelium. Bovine uveal preparations seem to be inactive when the epithelium has been removed. Purified outer segments are very active, as well as soluble extracts of outer segments. Highly purified bovine rhodopsin has no immunopathogenic activity. A soluble autoantigen (autoantigen S) has been isolated by preparative isoelectrofocusing from retinas of several species. Autoantigen S from guinea pig induces the disease in guinea pigs at a dose of a few micrograms.

Animals↗

[Experimental autoimmune uveo-retinitis (EAU): cellular immunity and humoral antibodies in the induction of ocular lesions and tolerance to retinal antigens].

EAU is induced in guinea pigs by one inoculation into the foot-pad of a retinal extract in complete Freund's adjuvant. The evolution of the antibodies (complement fixation) is compared with the évolution of the disease (intensity evaluated by frequent ophthalmological examinations). The successful passive transfer of the disease by local injections of immune serum and the demonstration by immunofluorescence of immune complexes in the ocular tissues are arguments for the role of humoral antibodies in the induction of the disease. EAUmay be inhibited by repeated subcutaneous or intradermal injections of the antigen, either before or after the onset of the inflammation. These injections depress the delayed hypersensitivity and increase the titre of complement fixing and passive anaphylactic antibodies.

Animals↗